Figure 2.

Spliceosome gene mutations found in myelodysplastic syndrome (MDS) patients enhance inflammatory cytokine production in cancer-relevant myeloid cells. (A-I) Cytokine mRNA levels were assayed in K562 cells carrying the indicated spliceosome gene mutations (red) or wild-type (WT) control genes (black). (J) IL-6 mRNA was analyzed in lipopolysaccharide (LPS)-induced (20 ng/mL LPS for 4 hours) peripheral blood monocytes isolated from MDS patients either carrying mutations in spliceosome genes (all splice, n=8, 3 SF3B1, 3 SRSF2, 2 U2AF1, color-coded red) or not carrying mutations in these three spliceosome genes (WT, color-coded black). Patient demographics are described in the Online Supplementary Table S1. (K-P) IL-6 mRNA was analyzed in the indicated myeloid cell types from mice engineered to express either WT human U2AF1 (black) or U2AF1-S34F (red). Data represent mean, Standard Error of Mean. *P<0.05. If no P-value is indicated, the comparison was not significantly different.